CLS strengthens the company's organization and management team
Clinical Laserthermia Systems AB (publ) (CLS), which develops advanced innovative products for high-precision image guided laser ablation, announces that the company is strengthening the organization and management team.
Liselotte Nilsson takes up a new position as "VP Marketing & Scientific Marketing". She has many years of experience in marketing management, marketing communication, both commercial and scientific, as well as product management from ProstaLund, Phase Holographic Imaging and Svar Life Science, among others. Liselotte holds a Master of Science in Molecular Biology from Lund University.
Anders Qvarlander succeeds Lotta Ljungberg, as VP Regulatory Affairs & Quality Assurance, and thus also joins the company's management team. Anders has extensive experience in managing market expansion, product registrations and quality assurance within the medical technology field from previous positions in Baxter, Arjo and Mediplast, among others.
Gunilla Savring leaves her operational role in the company as Chief Investor Relations Officer to move on to other assignments. Investor relations will be managed by acting CEO Dan Mogren and CFO Lars-Erik Eriksson until further notice.
"I welcome Liselotte Nilsson and Anders Qvarlander to CLS and look forward to working with them in the continued work to develop CLS's operations and establish TRANBERG as a strong brand within minimally invasive tissue ablation. I also thank Lotta Ljungberg and Gunilla Savring for the good work they have done for CLS and I wish them well in their new assignments," says Dan Mogren, former CEO of CLS.
The TRANBERG® |Thermal Therapy System has been developed for image-guided, high-precision soft tissue thermal therapy and ablation procedures. The system can be configured for MR, CT/US, and MR-US, Fusion-guided procedures using tissue temperature feedback for precise therapy and ablation control. It includes a desk-top mobile laser unit, innovative non-cooled laser applicators, external tissue temperature probe sensors, and procedure specific accessories. Its non-cooled, laser fiber technology optimizes heat distribution, eliminates the need for external cooling, and helps reduce procedure times. See published clinical studies.
This press release was submitted by the contact person below on 15th October 2021, at 13:00 PM CET
Dan J. Mogren, acting CEO, Clinical Laserthermia Systems AB (publ)
Ph: +46 – (0)705 – 90 11 40
E-mail: dan.mogren@clinicallaser.com
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy System, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and for treatment with imILT®, the Company's interstitial laser thermotherapy with potential immunostimulatory effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company's website: www.clinicallaser.se